WO2015005723A1 - 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 - Google Patents

세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 Download PDF

Info

Publication number
WO2015005723A1
WO2015005723A1 PCT/KR2014/006257 KR2014006257W WO2015005723A1 WO 2015005723 A1 WO2015005723 A1 WO 2015005723A1 KR 2014006257 W KR2014006257 W KR 2014006257W WO 2015005723 A1 WO2015005723 A1 WO 2015005723A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cancer
peptide
active ingredient
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2014/006257
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
김상재
손원준
박석우
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kael-GemVax Co Ltd
Original Assignee
Kael-GemVax Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kael-GemVax Co Ltd filed Critical Kael-GemVax Co Ltd
Priority to JP2016525289A priority Critical patent/JP6574175B2/ja
Priority to US14/903,827 priority patent/US9757473B2/en
Priority to KR1020167000554A priority patent/KR102224965B1/ko
Priority to CN201480050327.8A priority patent/CN105531284B/zh
Priority to EP14822442.1A priority patent/EP3020724A4/en
Publication of WO2015005723A1 publication Critical patent/WO2015005723A1/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Definitions

  • the pharmaceutical composition may be for the treatment or prevention of a disease.
  • Figure 6 is a graph showing the killing ability for cancer cells and normal cells according to the concentration when the conventional anti-cancer drug paclitaxel alone administered.
  • Korean Patent Application No. 10-2013-0082265 filed on July 12, 2013 and Korean Patent Application No. 10-2013-0165071 filed on December 27, 2013 are hereby incorporated by reference in their entirety for all purposes. Included. This application also claims the benefit of Korean Patent Application No. 10-2013-0082265 and Korean Patent Application No. 10-2013-0165071, which are hereby incorporated by reference in their entirety.
  • Another type of amino acid variant of the peptide is a change in the glycosylation pattern of the antibody.
  • change is meant the deletion of one or more carbohydrate residues found in the peptide and / or the addition of one or more glycosylation sites that are not present in the peptide.
  • Example 2 pep98 of Intracellular Input aspect analysis
  • the degree of cell death in cancer cell lines was measured by paclitaxel and paclitaxel-pep98 conjugates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/KR2014/006257 2013-07-12 2014-07-11 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 Ceased WO2015005723A1 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2016525289A JP6574175B2 (ja) 2013-07-12 2014-07-11 細胞透過性ペプチド、及びそれを含むコンジュゲート
US14/903,827 US9757473B2 (en) 2013-07-12 2014-07-11 Cell-penetrating peptide and conjugate comprising same
KR1020167000554A KR102224965B1 (ko) 2013-07-12 2014-07-11 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
CN201480050327.8A CN105531284B (zh) 2013-07-12 2014-07-11 细胞穿透肽和包含其的缀合物
EP14822442.1A EP3020724A4 (en) 2013-07-12 2014-07-11 Cell-penetrating peptide and conjugate comprising same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2013-0082265 2013-07-12
KR20130082265 2013-07-12
KR20130165071 2013-12-27
KR10-2013-0165071 2013-12-27

Publications (1)

Publication Number Publication Date
WO2015005723A1 true WO2015005723A1 (ko) 2015-01-15

Family

ID=52280308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/006257 Ceased WO2015005723A1 (ko) 2013-07-12 2014-07-11 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트

Country Status (6)

Country Link
US (1) US9757473B2 (enExample)
EP (1) EP3020724A4 (enExample)
JP (1) JP6574175B2 (enExample)
KR (1) KR102224965B1 (enExample)
CN (1) CN105531284B (enExample)
WO (1) WO2015005723A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757473B2 (en) 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
WO2022240055A1 (ko) * 2021-05-14 2022-11-17 주식회사 레메디 화물분자 수송 도메인 rmad1, 이의 변이체, 재조합 화물분자 및 이를 이용한 화물분자 수송 방법
WO2022255708A1 (ko) * 2021-06-03 2022-12-08 주식회사 레메디 화물분자 수송 도메인 rmmr1, 이의 변이체, 이를 포함하는 재조합 화물분자 및 이를 이용한 화물분자 수송 방법

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507961B (zh) 2012-05-11 2018-08-14 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN110074997B (zh) 2012-09-19 2022-07-08 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
CN104981478B (zh) 2012-09-19 2019-02-22 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
KR102911237B1 (ko) 2015-05-26 2026-01-13 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
CN120882737A (zh) 2023-02-23 2025-10-31 微肽技术有限公司 控制植物病原体的抗真菌肽

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225027A1 (en) * 2002-05-31 2003-12-04 Huang Jun Jian Telomerase reverse transcriptase fragments and uses thereof
KR20100085527A (ko) * 2009-01-21 2010-07-29 광주과학기술원 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
JP2010252810A (ja) * 1998-07-08 2010-11-11 Gemvax As テロメラーゼ由来抗原ペプチド
KR20120026408A (ko) * 2010-09-09 2012-03-19 서울대학교산학협력단 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
KR20130082265A (ko) 2012-01-11 2013-07-19 스키너스 주식회사 조적벽체 내진보강 구조

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0917579A1 (en) * 1997-07-01 1999-05-26 Cambia Biosystems LLC Vertebrate telomerase genes and proteins and uses thereof
GB0114719D0 (en) * 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
WO2003038047A2 (en) * 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
EP1495045B1 (en) * 2002-03-29 2009-09-02 Creagene, Inc. Cytoplasmic transduction peptides and uses thereof
ATE534661T1 (de) * 2006-10-12 2011-12-15 Angeletti P Ist Richerche Bio Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon
CN102321658A (zh) * 2011-07-20 2012-01-18 安徽农业大学 猪体细胞的重组蛋白诱变方法
KR101293620B1 (ko) * 2011-08-19 2013-08-13 국립암센터 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도
KR101444199B1 (ko) * 2012-02-20 2014-09-30 대한민국 세포막 투과용 단백질 및 그 용도
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
WO2014046481A1 (ko) * 2012-09-19 2014-03-27 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
KR102224965B1 (ko) 2013-07-12 2021-03-09 주식회사 젬백스앤카엘 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010252810A (ja) * 1998-07-08 2010-11-11 Gemvax As テロメラーゼ由来抗原ペプチド
US20030225027A1 (en) * 2002-05-31 2003-12-04 Huang Jun Jian Telomerase reverse transcriptase fragments and uses thereof
KR20100085527A (ko) * 2009-01-21 2010-07-29 광주과학기술원 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
KR20120026408A (ko) * 2010-09-09 2012-03-19 서울대학교산학협력단 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
KR20130082265A (ko) 2012-01-11 2013-07-19 스키너스 주식회사 조적벽체 내진보강 구조

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 20 August 2011 (2011-08-20), "TELOMERASE REVERSE TRANSCRIPTASE [PAN TROGLODYTES]", XP055308254, retrieved from NCBI Database accession no. AK62073.1 *
FONSECA ET AL: "Recent advances in the use of cell -penetrating peptides for medical and biological applications", ADVANCED DRUG DELIVERY REVIEWS, vol. 61, no. 11, 2009, pages 953 - 964, XP026666155 *
LEE ET AL: "Heat shock protein-mediated cell penetration and cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine", BIOMATERIALS, vol. 34, no. 30, 1 July 2013 (2013-07-01), pages 7495 - 7505, XP028679351 *
See also references of EP3020724A4

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757473B2 (en) 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
WO2022240055A1 (ko) * 2021-05-14 2022-11-17 주식회사 레메디 화물분자 수송 도메인 rmad1, 이의 변이체, 재조합 화물분자 및 이를 이용한 화물분자 수송 방법
WO2022255708A1 (ko) * 2021-06-03 2022-12-08 주식회사 레메디 화물분자 수송 도메인 rmmr1, 이의 변이체, 이를 포함하는 재조합 화물분자 및 이를 이용한 화물분자 수송 방법

Also Published As

Publication number Publication date
CN105531284B (zh) 2021-03-23
US9757473B2 (en) 2017-09-12
KR102224965B1 (ko) 2021-03-09
EP3020724A1 (en) 2016-05-18
JP6574175B2 (ja) 2019-09-11
CN105531284A (zh) 2016-04-27
KR20160029069A (ko) 2016-03-14
EP3020724A4 (en) 2017-01-18
JP2016523558A (ja) 2016-08-12
US20160158374A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
WO2015005723A1 (ko) 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
WO2014046478A1 (ko) 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
WO2014046490A1 (ko) 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
EP1811033B1 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2013169077A1 (ko) 악액질 예방 또는 치료용 조성물
WO2015156649A1 (ko) 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
KR20220123294A (ko) 폴리펩티드, 이의 제조방법 및 용도
WO2019212324A1 (ko) 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화
WO2015076621A1 (ko) 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
WO2015057009A1 (ko) 알파나선형 세포 투과 펩타이드 다합체, 이의 제조방법 및 그 용도
WO2014183491A1 (zh) 具有抗肿瘤活性的多肽及其用途
KR101368607B1 (ko) 메타스틴 유도체 및 그의 용도
WO2015093854A1 (ko) 전립선 암 치료용 조성물
WO2016190660A1 (ko) 신규 펩티드 및 이를 포함한 조성물
JP2021510538A (ja) タンパク質性分子およびその使用
WO2022215946A1 (ko) 세포 투과성 펩타이드 변이체 및 이의 용도
WO2021194186A1 (ko) Vgll1 펩타이드를 포함하는 암 치료용 조성물
WO2024054062A1 (ko) 세포 내 형질주입을 위한 신규한 폴리펩타이드 조성물
WO2023003380A1 (ko) 신규 세포 투과성 펩타이드 및 이의 용도
WO2016098936A1 (ko) 골형성 펩타이드 및 이의 용도
KR102398339B1 (ko) 일산화질소 전달용 융합 펩타이드 및 이의 용도
AU2017214761B2 (en) Proteinaceous compounds and uses therefor
WO2023277628A1 (ko) 신규한 세포 투과성 펩타이드 및 이의 용도
WO2023017976A1 (ko) 양이온성 세포 투과성 펩타이드 및 이의 용도
WO2023191190A1 (ko) 종양으로의 약물 전달을 위한 뉴로필린 1에 특이적으로 결합하는 종양 조직 침투성 펩타이드 및 이의 용도

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480050327.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14822442

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20167000554

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2016525289

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14903827

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014822442

Country of ref document: EP